Literature DB >> 28027934

Histone modifications in FASN modulated by sterol regulatory element-binding protein 1c and carbohydrate responsive-element binding protein under insulin stimulation are related to NAFLD.

Xuan Du1, Can Cai1, Jialing Yao1, Youping Zhou1, Huihong Yu1, Wei Shen2.   

Abstract

Non-alcoholic fatty liver disease (NAFLD) and its causal factors of hepatic insulin resistance (IR) and type 2 diabetes are rapidly growing worldwide. Developing new therapeutic methods for these conditions requires a comprehensive understanding between hepatic lipid metabolism and IR. Sterol regulatory element-binding transcription factor 1c (SREBP-1c) and carbohydrate responsive-element binding protein (ChREBP) are the major regulators of fatty acid synthase (FASN), a key enzyme of de novo fatty acid synthesis. They are induced by insulin, which directly binds to the sterol regulatory elements (SRE) or carbohydrate-responsive elements (ChORE) of the FASN promoter to induce its expression. The insulin pathway involved in NAFLD has well studied, but the role of histone modification in NAFLD is just beginning to be investigated, and there is minimal data regarding its involvement. In the current study, we investigated histone modifications in FASN under insulin stimulation. H3K4 hypertrimethylation and H3, H4 hyperacetylation in the FASN promoter was found in HepG2 cells and primary hepatocytes following insulin stimulation. We also found that insulin treatment induced the transcription factor SREBP-1c, ChREBP and could accelerate FASN expression by enhancing SREBP-1c, SRE, and ChREBP ChORE binding and inducing H3, H4 hyperacetylation at SRE, ChORE, or transcription start site (TSS) regions of the FASN promoter in hepatocellular carcinoma cell line (HepG2) and primary hepatocytes. Finally, histone acetylation could influence FASN expression by impairing SREBP-1c SRE and ChREBP ChORE binding.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ChREBP; Hepatocyte steatosis; Histone modification; IR; NAFLD; SREBP-1c

Mesh:

Substances:

Year:  2016        PMID: 28027934     DOI: 10.1016/j.bbrc.2016.12.129

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  5 in total

1.  FTY720/fingolimod decreases hepatic steatosis and expression of fatty acid synthase in diet-induced nonalcoholic fatty liver disease in mice.

Authors:  Timothy D Rohrbach; Amon Asgharpour; Melissa A Maczis; David Montefusco; L Ashley Cowart; Pierre Bedossa; Arun J Sanyal; Sarah Spiegel
Journal:  J Lipid Res       Date:  2019-05-20       Impact factor: 5.922

2.  The Administration of Chitosan-Tripolyphosphate-DNA Nanoparticles to Express Exogenous SREBP1a Enhances Conversion of Dietary Carbohydrates into Lipids in the Liver of Sparus aurata.

Authors:  Jonás I Silva-Marrero; Juliana Villasante; Ania Rashidpour; Mariana Palma; Anna Fàbregas; María Pilar Almajano; Ivan Viegas; John G Jones; Montserrat Miñarro; Josep R Ticó; Isabel V Baanante; Isidoro Metón
Journal:  Biomolecules       Date:  2019-07-24

3.  Zhenqing recipe relieves diabetic nephropathy through the SIK1/SREBP-1c axis in type 2 diabetic rats.

Authors:  Qiuhong Liao; Wenguang Xu; Qiong Luo; Xiuying Wen
Journal:  Am J Transl Res       Date:  2021-12-15       Impact factor: 4.060

4.  Inhibition of stearoyl-coenzyme A desaturase 1 ameliorates hepatic steatosis by inducing AMPK-mediated lipophagy.

Authors:  Youping Zhou; Li Zhong; Shengjie Yu; Wei Shen; Can Cai; Huihong Yu
Journal:  Aging (Albany NY)       Date:  2020-04-23       Impact factor: 5.682

Review 5.  Epigenetic regulation of histone H3 in the process of hepatocellular tumorigenesis.

Authors:  Dan Li; Zhenguo Zeng
Journal:  Biosci Rep       Date:  2019-08-02       Impact factor: 3.840

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.